Attainment of the Japanese Society for Dialysis Therapy Guidelines for the Management of Secondary Hyperparathyroidism in Chronic Hemodialysis Patients in Our Clinic

2007 ◽  
Vol 11 (s1) ◽  
pp. S48-S53
Author(s):  
Yuzuru Sato ◽  
Rieko Eriguchi ◽  
Junko Umakoshi ◽  
Masakazu Kato
2004 ◽  
Vol 8 (6) ◽  
pp. 443-459 ◽  
Author(s):  
Fumitake Gejyo ◽  
Akira Saito ◽  
Tadao Akizawa ◽  
Takashi Akiba ◽  
Tatsuya Sakai ◽  
...  

2006 ◽  
Vol 10 (5) ◽  
pp. 449-462 ◽  
Author(s):  
Seiji Ohira ◽  
Hidemune Naito ◽  
Izumi Amano ◽  
Nakanobu Azuma ◽  
Kiyoshi Ikeda ◽  
...  

2015 ◽  
Vol 19 ◽  
pp. 1-39 ◽  
Author(s):  
Kazutaka Kukita ◽  
Seiji Ohira ◽  
Izumi Amano ◽  
Hidemune Naito ◽  
Nakanobu Azuma ◽  
...  

2012 ◽  
Vol 16 (5) ◽  
pp. 387-435 ◽  
Author(s):  
Hideki Hirakata ◽  
Kosaku Nitta ◽  
Masaaki Inaba ◽  
Tetsuo Shoji ◽  
Hideki Fujii ◽  
...  

2020 ◽  
Vol 9 (3) ◽  
pp. 629 ◽  
Author(s):  
Mariadelina Simeoni ◽  
Alessandra F. Perna ◽  
Giorgio Fuiano

Secondary hyperparathyroidism (SHPTH) is a major complication in patients on maintenance hemodialysis burdened with high cardiovascular risk. Hypertension is also a high prevalence complication contributing to an increase in the mortality rate in hemodialysis patients. A possible association between SHPTH and hypertension has been widely reported in the literature and several pathogenetic mechanisms have been described. There is evidence that the decrease of plasma iPTH levels are correlated with hypertension correction in hemodialysis patients undergoing parathyroidectomy and oral calcimimetics administration. We have observed a similar behaviour also in a patient on chronic hemodialysis treated with Etelcalcetide. Even if this is an isolated observation, it could stimulate future investigation, possibly in dedicated clinical trials.


Sign in / Sign up

Export Citation Format

Share Document